List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Overview
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Advenchen Laboratories LLC
Aeterna Zentaris Inc
Amgen Inc
AstraZeneca Plc
Chipscreen Biosciences Ltd
Cielo Therapeutics Inc
Sanofi
Sareum Holdings Plc
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Drug Profiles
AL-8326 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-2811 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-2164 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danusertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBPR-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMI-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-156497 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Aurora B Kinase and ERK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Dormant Products
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Discontinued Products
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Dec 21, 2017: Sundia Congratulates NHRI for DBPR114 IND Approval in US & Taiwan
Aug 03, 2016: China and Hong Kong Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors
May 10, 2016: Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics
Feb 10, 2016: AZD2811 ACCURINS Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies
Nov 18, 2015: BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors
Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors
Jun 23, 2015: BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811
Apr 22, 2015: BIND Therapeutics Presents Data Highlighting Ability of Accurin drug candidate AZD2811 to Accumulate in Target Tissue at AACR Annual Meeting 2015
Mar 18, 2015: Data from Abstracts Validating Potential of BIND Therapeutics AZD2811 to be Presented at American Association for Cancer Research Annual Meeting
Mar 05, 2014: BIND Therapeutics to Present Data on Barasertib at the AACR 2014 Annual Meeting
Jul 15, 2013: Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor Programme
Sep 03, 2012: Chipscreen filed a new IND application on a novel dual-pathway targeted inhibitor Chiauranib to SFDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by Advenchen Laboratories LLC, H1 2018
Pipeline by Aeterna Zentaris Inc, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Chipscreen Biosciences Ltd, H1 2018
Pipeline by Cielo Therapeutics Inc, H1 2018
Pipeline by Sanofi, H1 2018
Pipeline by Sareum Holdings Plc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Dormant Products, H1 2018 (Contd..3), H1 2018
Dormant Products, H1 2018 (Contd..4), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

Companies Mentioned
• AbbVie Inc
• Advenchen Laboratories LLC
• Aeterna Zentaris Inc
• Amgen Inc
• AstraZeneca Plc
• Chipscreen Biosciences Ltd
• Cielo Therapeutics Inc
• Sanofi
• Sareum Holdings Plc